Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Multiple Myeloma

Oncolyze, which already holds an Orphan Drug Designation for its lead drug candidate OM-301 in treating acute myeloid leukemia, announced that the FDA has just granted OM-301 its second Orphan Drug Designation, for multiple myeloma.